University Post-graduate Course - Clinical Oncology: Head & neck cancers
24 ESCO credits
05.02.2018 - 09.02.2018
Milan, Italy
COURSES AND SEMINARS
Head and neck cancers, Medical / clinical oncology, Rare cancers, Rare head and neck cancers
Description
Scientific Coordinator: L. Licitra, IT
The University of Milan, Italy, in close collaboration with the European School of Oncology, will organise the first post-graduate course on clinical oncology of head and neck cancers.
This programme is addressed to an international audience of clinical oncologists interested in advancing their knowledge and skills on the clinical management of head and neck cancers in a multidisciplinary context. It will last one week for a total of 30 teaching hours and the official language will be English.
We are aware that “networking” is the keyword in improving quality of care of rare cancers.
Both ESO and the University of Milan are involved as associated partners in the new established EURACAN, the European Reference Network on rare adult solid cancers. Thus, this educational effort aims to reinforce the collaboration among oncologists of different countries who are already involved in EURACAN, or in networks related to EURACAN, or willing to be part of it in the near future.
Admission to the course will be on competitive application only. Attendance is limited to 30 participants.
LEARNING OBJECTIVES
• To provide an overview of current multidisciplinary state-of-the-art treatment of head and neck cancers
• To discuss relevant clinical cases on a multidisciplinary basis
• To establish connections for future distance clinical mentoring/tutoring/networking
| The post-graduate course is a Università degli Studi di Milano-ESO joint initiative | ||||||||||
| Held in collaboration with | In the framework of | |||||||||
 |
 |
 |
||||||||
Faculty
FACULTY
S. Alfieri, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
P. Bossi, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
A. Caraceni, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
C. Fallai, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
G. Gatta, Fondazione IRCCS Istituto Nazionale Tumori, Milano IT
C . Gavazzi, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
V. Gregoire, Universitè Catholique, Louvain, BE
A. Iacovelli, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
L. Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
P. Morbini, Department of Pathology, University of Pavia, IT
P. Nicolai, ASST Spedali Civili, Brescia, IT
R. Orecchia, Istituto Europeo di Oncologia, Milan, IT
E. Orlandi, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
G. Pravettoni, Istituto Europeo di Oncologia, Milan, IT
L. Preda, Istituto Europeo di Oncologia, Milano, IT
A. Schindler, Department of Clinical and Biomedical Sciences, University of Milan, IT
C. Simon, Université de Lausanne, CHUV Lausanne, CH
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milano IT
General information
ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
Marina Fregonese
email: mfregonese@eso.net
phone: +39 02 23902106
VENUE
University of Milan
Room InfoGiure
Via Festa del Perdono, 3/7
Milan, IT
ACCREDITATION
Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising Secretariat.
OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.
Programme
5 February
| INTRODUCTION | ||
| 13:30 | Registration |
|
| 14:00 | Introduction - The natural history and biology L. Licitra, IT - L. Locati, IT |
|
| 15:00 | The epidemiology G. Gatta, IT |
|
| 16:00 | Imaging L. Preda, IT |
|
| 17:00 | The pathology P. Morbini, IT |
|
6 February
| ORAL CAVITY (OC) AND OROPHARYNGEAL CANCER (OPC) |
||
| 9:00 | Surgery of OC C. Simon, CH |
|
| 10:00 | Radiation of OC C. Fallai, IT |
|
| 11:00 | HPV in OPC L. Licitra, IT - G. Pravettoni, IT |
|
| 12:00 | Principles of treatment of OPC V. Gregoire, BE |
|
| 13:00 |
Interval |
|
| 14:00 | Transoral surgery of OPC C. Piazza, IT |
|
| 15:00 | Radiation treatment of OPC E. Orlandi, IT |
|
| 16:00 | Chemotherapy in OPC L. Licitra, IT |
|
| 17:00 | Medical therapy of recurrent and metastatic disease L. Locati, IT |
|
7 February
| CANCERS OF LARYNX AND HYPOPHARYNX |
||
| 9:00 | Surgery in early and advanced stage disease C. Piazza, IT - P. Nicolai, IT |
|
| 10:00 | Radiation in early and advanced stage disease C. Fallai, IT |
|
| 11:00 | Principles of organ preservation L. Licitra, IT |
|
| 12:00 | Rehabilitation A. Schindler, IT |
|
| 13:00 | Interval |
|
| 14:00 | Supportive care and nutrition in the curative setting S. Alfieri, IT - C . Gavazzi, IT |
|
| 15:00 | Salvage surgery C. Piazza, IT |
|
| 16:00 | Re-irradiation C. Fallai, IT |
|
8 February
| RARE CANCERS OF THE HEAD AND NECK |
||
| 9:00 | Nasopharyngeal cancer E. Orlandi, IT |
|
| 10:00 | Surgery in nasal cavity and paranasal cancers P. Nicolai, IT |
|
| 11:00 | Radiation therapy in nasal cavity and paranasal cancers A. Iacovelli, IT |
|
| 12:00 | Hadron therapy in nasal and paranasal sinus cancers R. Orecchia, IT |
|
| 13:00 |
Interval |
|
| 14:00 | Multimodality treatment in nasal cavity and paranasal sinus cancers P. Bossi, IT |
|
| 15:00 | Salivary gland cancers L. Licitra, IT |
|
| 16:00 | The problems of rare cancers and the EU initiatives P.G. Casali, IT - A. Trama, IT |
|
9 February
| ISSUES IN HEAD AND NECK CANCERS |
||
| 9:00 | The elderly patient P. Bossi, IT |
|
| 10:00 | The problems of multidisciplinarity L. Licitra, IT |
|
| 11:00 | Palliative challenges in recurrent and metastatic disease A. Caraceni, IT |
|
| 12:00 | The medical collaboration and patient decision making G. Pravettoni, IT |
|
| 13:00 | End of the course ad CME questionnaire L. Licitra, IT |
|